Arformoterol tartrate

Base Information

• Chemical Name: Arformoterol tartrate
• CAS No.: 200815-49-2
• Deprecated CAS: 208102-41-4
• Molecular Formula: C19H24N2O4^.C4H6O6
• Molecular Weight: 494.49
• European Community (EC) Number: 696-617-3
• UNII: 5P8VJ2I235
• DSSTox Substance ID: DTXSID80173903
• Wikidata: Q27262686
• NCI Thesaurus Code: C65240
• RXCUI: 668284
• Mol file: 200815-49-2.mol

Synonyms:Arformoterol tartrate;200815-49-2;Brovana;(R,R)-Formoterol tartrate;(R,R)-Arformoterol tartrate;Arformoterol Tartrate [USAN];UNII-5P8VJ2I235;5P8VJ2I235;Brovana (TN);Arformoterol tartrate (USAN);Formamide, N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1);(-)-N-(2-Hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)formamide hydrogen (2R,3R)-2,3-dihydroxybutanedioate (salt);Formamide, N-(2-hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt);N-[2-Hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-formamide (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt);(R,R)-Eformoterol tartrate;Arformotero ltartrate;DTXSID80173903;FCSXYHUNDAXDRH-OKMNHOJOSA-N;C19H24N2O4.C4H6O6;ARFORMOTEROL TARTRATE [VANDF];s5217;ARFORMOTEROL TARTRATE [MART.];AKOS005145740;ARFORMOTEROL TARTRATE [WHO-DD];CCG-269651;CS-O-00839;Arformoterol tartrate, >=98% (HPLC);BA171831;BS-42158;ARFORMOTEROL TARTRATE [ORANGE BOOK];C19-H24-N2-O4.C4-H6-O6;FORMOTEROL R,R-FORM L-TARTRATE [MI];D02981;Q-101035;Q27262686;(2R,3R)-2,3-dihydroxybutanedioic acid;N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;N-(2-Hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)formamide (2R,3R)-2,3-dihydroxybutanedioate (1:1);[(2R)-2-(3-formamido-4-hydroxyphenyl)-2-hydroxyethyl]-[(2R)-1-(4-methoxyphenyl)propan-2-yl]azanium;(2R,3R)-2,3,4-trihydroxy-4-oxobutanoate;N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide (2R,3R)-2,3-dihydroxybutane dioate;N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide (2R,3R)-2,3-dihydroxybutanedioate;N-[2-Hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide L-tartrate

Chemical Property of Arformoterol tartrate

Chemical Property:

• Vapor Pressure: 2.12E-15mmHg at 25°C
• Melting Point: 184°
• Boiling Point: 603.2 °C at 760 mmHg
• Flash Point: 318.6 °C
• PSA: 205.88000
• LogP: 1.20050
• Storage Temp.: Refrigerator, Under Inert Atmosphere
• Solubility.: DMSO (Slightly, Sonicated), Methanol (Slightly, Heated, Sonicated), Water (Sligh
• Hydrogen Bond Donor Count: 8
• Hydrogen Bond Acceptor Count: 11
• Rotatable Bond Count: 11
• Exact Mass: 494.19004516
• Heavy Atom Count: 35
• Complexity: 521

Purity/Quality:

99% ^*data from raw suppliers

ArformoterolTartrate ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O.C(C(C(=O)O)O)(C(=O)O)O
• Isomeric SMILES: C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
• Recent ClinicalTrials: Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)
• Description: Sepracor’s Brovana?, a nebulized long acting bronchodilator, was launched in the U.S. in April 2007. The β2- adrenoceptor agonist is indicated for the twice-daily, longtermmaintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema. It is the first long-acting nebulized bronchodilator approved by the FDA for this indication. Aformoterol is the (R,R)-enantiomer of the β2-adrenergic receptor (β2-AR) agonist formoterol . It selectively binds to β1- over β2-ARs (Kds = 2.9 and 113 nM, respectively) as well as β3-adrenergic, B2 bradykinin, neurokinin 1 (NK1) and NK2 receptors when used at concentrations up to 3 μM. Aformoterol induces cAMP accumulation in cultured human bronchial epithelial cells. Ex vivo, aformoterol (0.01-1,000 nM) induces dose-dependent relaxation of guinea pig tracheal strips precontracted with carbamoylcholine , ovalbumin, or histamine (pD2s = 8.4, 9.5, and 9.5, respectively). In vivo, aformoterol reverses histamine- and ovalbumin-induced bronchoconstriction in guinea pigs (ED50s = 1 and 40 nmol/kg, respectively). Formulations containing aformoterol have been used in the treatment of chronic obstructive pulmonary disease (COPD).
• Uses: Arformoterol Tartrate, can be used in the synthesis of Omeprazole (O635000), which is a proton pump inhibitor, that inhibits gasteric secretion, also used in the treatment of dyspepsia, peptic ulcer disease, etc. It is also the impurity of Esomeprazole Magnesium (E668300), which is the S-form of Omeprazole, and is a gastric proton-pump inhibitor. Also, It can be used for the preparation of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24h bronchodilatory efficacy. Anti-asthmatic and bronchodilator.